Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

PHASE2TerminatedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

December 31, 2010

Conditions
Liver Cirrhosis, Biliary
Interventions
DRUG

INT-747

Once a day (QD) by mouth (PO)

DRUG

Ursodeoxycholic Acid (URSO)

Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.

DRUG

Placebo

Placebo

Trial Locations (32)

3000

Erasmus Medical Centre, Rotterdam

10003

Beth Israel Medical Center, New York

10029

Mt. Sinai School of Medicine, New York

23249

McGuire DVAMC, Richmond

30623

Medical School of Hannover, Hanover

32610

U Florida Hepatology, Gainesville

33136

University of Miami - Center for Liver Diseases, Miami

44195

Cleveland Clinic, Cleveland

48377

Henry Ford Health Center Columbus, Novi

60590

Johann Wolfgang Goethe University, Frankfurt

63104

Saint Louis University, St Louis

69288

Hopital de l'Hotel Dieu, Lyon

75390

UT Southwestern Medical Center, Dallas

77030

Baylor College of Medicine, Houston

98101

Virginia Mason Medical Center, Seattle

555905

Mayo Clinic, Rochester

02111

Tufts Medical Center, Boston

A8036

Karls-Franzens University, Graz

T2N 4N1

University of Calgary, Calgary

T5G 2X8

University of Alberta, Edmonton

R3E 3P4

University of Manitoba, Winnipeg

M5T2S8

University of Toronto Western Hospital, Toronto

H2X 1P1

Centre de Recherche du CHUM / University of Montreal, Montreal

D20246

University Medical Centre Hamburg-Eppendorf, Hamburg

D81377

University of Munich, Munich

NL-1100

AMC University of Amsterdam, Amsterdam

08036

Hospital Clinic i Provincial, Barcelona

B15 2TH

Queen Elizabeth Medical Center, Edgbaston

NW3 2QG

Royal Free Hospital, Hampstead

OX3 9DU

John Radcliffe Hospital, Headington

EH16 4SA

Royal Infirmary, Edinburgh

NE2 4HH

University Upon Tyne/Newcastle, Newcastle upon Tyne

Sponsors
All Listed Sponsors
lead

Intercept Pharmaceuticals

INDUSTRY